Литература к статье «Кларитромицин: есть ли потенциал для клинического использования
в XXI веке?» (С.А. Рачина, Л.С. Страчунский, Р.С. Козлов)
1. Forrest G.N., Oldach D.W. Macrolides and clindamycin. In: Gorbach S.L., Bartlett J.G.,
Blacklow N.R., editors. Infectious Diseases. Lippincott Williams and Wilkins, 3d edition,
2004, 213-33.
2. Bryskier A. and Butzler J.-P. Macrolides. In: Finch R.G., Greenwood D., Norrby S.R.,
Whitley R.J., editors. Antibiotic and Chemotherapy. Anti-infective agents and their use in
therapy. Churchill Livingstone, 8th edition, 2003, p. 310-25.
3. Neu H.C. The development of macrolides: clarithromycin in perspective. J Antimicrob
Chemother 1991; 27 (Suppl A):1-9.
4. McCaig L.F., Besser R.E., Hughes J.M. Antimicrobial drug prescription in ambulatory care
settings, United States, 1992-2000. Emerg Infect Dis 2003; 9(4):432-437.
5. Mazzei T., Mini E., Novelli A., Periti P. Che-mi--stry and mode of action of macrolides. J
Anti-microb Chemother 1993; 31 (Suppl C):1-9.
6. C.J. Carbon, E. Rubinstein. Macrolides, ketolides, lincosamides and streptogramins. In: J.
Cohen, W.G. Powderly, S.M. Opal, S.F. Berkley, T. Calandra, N. Clumeck, e.a., editors.
Infectious Diseases. Elsevier Limited, 2nd edition, 2004, p. 1791-1803.
7. S. Sivapalasingam, N.H. Steigbigel. Macrolides, clindamycin, and ketolides. In: G.L. Mandell,
J.E. Bennett, R. Dolin, editors. Pronciples & Practice of Infectious Diseases. Churchill
Livingstone, 6th edition, 2004, p. 396-417.
8. Bergeron MG, Bemier M, L‘Ecuyer J. In vitro activity of clar-ithromycin and its 14-hydroxymetabolite against 203 strains of Haemophilus influenzae. Infection 1992; 20:164-167.
9. Malanoski G.J., Eliopoulos G.M., Ferraro M.J., Moellering R.C. Jr. Effect of pH variation on
the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and
temafloxacin. Eur J Clin Microbiol Infect Dis. 1993; 12:131-3.
10. Loo V.G., Fallone C.A., De Souza E., Lavallee J., Barkun A.N. In-vitro susceptibility of
Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole. J
Antimicrob Chemother 1997; 40:881-883.
11. Doucet-Populaire F., Capobianco J.O., Zakula D., Jarlier V., Goldman R.C. Molecular basis
of clarithromycin activity against Mycobacterium avium and Mycobacterium smegmatis. J
Antimicrob Chemother 1998; 41:179-187.
12. Doucet-Populaire F., Buriankova K., Weiser J., Pernodet J.L. Natural and acquired macrolide
resistance in mycobacteria. Curr Drug Targets Infect Disord 2002; 2:355-370.
13. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the
resistance elements and their clinical implications. Clin Infect Dis 2002; 34:482-492.
14. Edelstein P.H. Pneumococcal resistance to macrolides, lincosamides, ketolides, and
streptogramin B agents: molecular mechanisms and resistance phenotypes.
Clin Infect Dis 2004; 38 (Suppl 4):S322-327.
15. Bingen E., Leclercq R., Fitoussi F., Brahimi N., Malbruny B., Deforche D., Cohen R.
Emergence of group A Streptococcus strains with different mechanisms of macrolide
resistance. Antimicrob Agents Chemother 2002; 46:1199-1203.
16. Megraud F. Basis for the management of drug-resistant Helicobacter pylori infection. Drugs
2004; 64:1893-1904.
17. Kozlov R.S., Bogdanovitch T.M., Appelbaum P.C., Ednie L., Stratchounski L.S., Jacobs
M.R., Bozdogan B. Antistreptococcal activity of telithromycin compared with seven other
drugs in relation to macrolide resistance mechanisms in Russia. Antimicrob Agents
Chemother 2002; 46:2963-2968.
18. Matsuoka M., Sasaki T. Inactivation of macrolides by producers and pathogens. Curr Drug
Targets Infect Disord 2004; 4:217-240.
19. Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 1999;
37:385-398.
20. Abbott Laboratories. Biaxin® Prescribing Information. Available from
http://biaxin.com/bixhome/bixhome.htm.
21. Chu S., Deaton R., Cavanaugh J. Absolute bioavailability of clarithromycin after oral
administration in humans. Antimicrob Agents Chemother 1992; 36:1147-1150.
22. Guay D.R.P., Gustavson L.E., Devcich K.J., Zhang J., Cao G., Olson CA. Pharmaco-kinetics
and tolerability of extended-release clarithromycin. Clin Ther 2001: 23:566-577.
23. Gotfried M.H. Clarithromycin (Biaxin) extended-release tablet: a therapeutic review.
Expert Rev Anti Infect Ther 2003; 1:9-20.
24. Bearden DT, Rodvold KA. Practical pharmacology - penetration of macrolides into
pulmonary sites of infection. Infect Med 1999; 16:480A-484A.
25. Rodvold K.A., Gotfried M.H., Danziger L.H., Sorvi R.J. Intrapulmonary steady-stale
concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob
Agents Chemother 1997; 41:1399-1402.
26. Fish D.N., Gotfried M.H., Danziger L.H., Rodvold K.A. Penetration of clarithromycin into
lung tissues from patients undergoing lung resection. Antimicrob Agents Chemother 1994;
38:876-888.
27. Gotfried M.H., Danziger L.H., Rodvold K.A. Steady-state plasma and bronchopulmonary
characteristics of clarithromycin extended-release tablets in normal healthy adult
subjects.JAC 2003; 52:450-456.
28. Fietta A., Merlini C., Gialdroni Grassi G. Requirements for intracellular accumulation and
release of clarithromycin and azithromycin by human phagocytes. J Chemother 1997; 9:2331.
29. Kees F, Wellenhofer M, Grobecker H. Serum and cellular pharmacokinetics of clarithromycin 500 mg q.d. and 250 mg b.i.d. in volunteers. Infection 1995; 23:168-172.
30. Craft J.C., Siepman N. Overview of the safety profile of clar-ithromycin suspension in
pediatric patients. Pediatr Infect Dis J 1993; 12 (Suppl 3):S142-147.
31. Guay D.R., Patterson D.R., Seipman N., Craft J.C. Overview of the tolerability profile of
clarithromycin in preclinical and clinical trials. Drug Saf 1993; 8:350-364.
32. Kolkman W., Groeneveld J.H., Baur H.J., Verschuur H.P. Ototoxicily induced by
clarithromycin. Ned Tijdschr Geneeskd. 2002; 146:1743-1745.
33. Roussel G., Igual J. Clarithromycin with minocycline and clofazimine for Mycobacterium
avium intracellulare complex lung disease in patients without the acquired immune deficiency
syndrome. GETIM. Groupe d’Etude et de Traitement des Infections a Mycobacteries. Int J
Tuberc Lung Dis 1998; 2:462-470.
34. Gomez-Gil E., Garcia F., Pintor L., Martinez J.A., Men-sa J., de Pablo J. Clarithromycininduced acute psychoses in peptic ulcer disease. Eur J Clin Microbiol Infect Dis 1999; 18:7071.
35. Prime K., French P. Neuropsychiatric reaction induced by clarithromycin in a patient on
highly active antiretroviral therapy (HAART). Sex Transm Infect 2001; 77:297-298.
36. de Dios Garcia-Diaz J., Santolaya Perrin R., Paz Martinez Ortega M., Moreno-Vazquez M.
Phlebitis due to intravenous administration of macrolide antibiotics. A comparative study of
erythromycin versus clarithromycin. Med Clin 2001;116:133-5.
37. Fogarty C., Grossman С., Williams J., Haverstock D., Church D. Efficacy and safety of
moxifloxacin vs. clarithromycin for community-acquired pneumonia. Inf Med 1999; 16:748763.
38. Ramirez J., Unowsky J., Talbot G.H., Zhang H., Town-send L. Sparfloxacin vs.
clarithromycin in the treatment of community-acquired pneumonia. Clin Ther 1999; 21:103116.
39. McCarty J.M., Pierce P.F. Five days of cefprozil versus 10 days of clarithromycin in the
treatment of an acute exacerbation of chronic bronchitis. Ann Allergy Asthma Immunol 2001;
87:327-334.
40. Lode H., Eller J., Linnhoff A., Ioanas M.; Evaluation of Therapy-Free Interval in COPD
Patients Study Group.Levofloxacin versus clarithromycin in COPD exacerbation: focus on
exacerbation-free interval. Eur Respir J 2004; 24:947-953.
41. McCarty J., Hedrick J.A., Gooch W.M. Clarithromycin suspension vs penicillin V
suspension in children with streptococcal pharyngitis. Adv Ther 2000; 17:14-26.
42. Devcich K., Busman T., Olson C., Notario G. Adverse event severity comparisons with
extended-release clarithromycin and immediate-release clarithromycin. In: Proceedings of the
Program and Abstracts of the 40th Annual Meeting of the Infectious Diseases Society of
America, Chicago, IL, 24-27 October 2002 [abstract 212].
43. Westphal J.F. Macrolide - induced clinically relevant drug interactions with cytochrome P450A (CYP) 3A4: an update focused on clarithro--mycin, azithromycin and dirithro-mycin.
Br J Clin Pharmacol 2000; 50:285-295.
44. Gustavson L.E., Kaiser J.F., Edmonds A.L., Locke C.S., DeBartolo M.L., Schneck D.W.
Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at
steady state. Antimicrob Agents Chemother 1995; 39:2078-2083.
45. Saito M., Yasui-Furukori N., Uno T., Takahata T., Suga-wara K., Munakata A., Tateishi T.
Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. Br
J Clin Pharmacol 2005; 59:302-309.
46. Berning S.E., Peloquin C.A. Adverse events associated with high-dose rifabutin in
macrolide-containing regimens for the treatment of Mycobacterium avium complex lung
disease. Clin Infect Dis 1996; 22:885.
47. Polis M.A., Piscitelli S.C., Vogel S., Witebsky F.G., Conville P.S., Petty B., et al.
Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency
virus infection. Antimicrob Agents Chemother 1997; 41:1709-1714.
48. R. Van Heeswijk, J. Sabo, T. Macgregor, M. Elgadi, F. Harris, S. Mccallister, D.Mayers. The
effect of tipranavir/ritonavir 500/200 mg bid on the pharmacokinetics of clarithromycin in
healthy volunteers. In: Abstracts of the 44th Annual Interscience Conference on
Antimicrobial Agents and Chemotherapy, Chicago, IL, 14-17 September 2004 [abstract 457].
49. Hung I.F., Wu A.K., Cheng V.C., Tang B.S., To K.W., Yeung C.K., et al. Fatal interaction
between clarithromycin and colchicines in patients with renal insufficiency: a retrospective
study. Clin Infect Dis 2005; 41:291-300.
50. P.C. Woo, S.K. Lau, K.-Y. Yuen. Macrolides as immunomodulatory agents. Curr Med Chem
- Anti-Inflammatory & Anti-Allergy Agents 2002; 1:131-141.
51. Culic O. Erakovic V. Pamham M.J. Anti-inflammatory effects of macrolide antibiotics. Eur J
Pharmacol 2001; 429:209-229.
52. Labro M.T., Abdelghaffar H. Immunomodulation by macrolide antibiotics. Journal of
Chemotherapy 2001; 13:3-8.
53. Tamaoki J. The effects of macrolides on inflammatory cells. Chest 2004; 125:41S-51S.
54. Demartini G., Esposti D., Marthyn P., Lapidari A., Fra-schi-ni F., Scaglione F. Effect of
multiple doses of clarithromycin and amoxicillin on IL-6, IFNgamma and IL-10 plasma levels
in patients with community acquired pneumonia. J Chemother 2004; 16:82-85.
55. Tamaoki J., Takeyama K., Tagaya E., Konno K. Effect of clarithromycin on sputum
production and its rheological properties in chronic respiratory tract infections.
Antimicrob Agents Chemother 1995; 39:1688-1690.
56.. Tagaya E., Tamaoki J., Kondo M., Nagai A. Effect of a short course of clarithromycin
therapy on sputum production in patients with chronic airway hypersecretion.
Chest 2002; 122:213-218.
57. Rubin B.K., Druce H., Ramirez O.E., Palmer R. Effect of clarithromycin on nasal mucus
properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care
Med 1997; 155:2018-2023.
58. Molinari G., Guzman C.A., Pesce A., Schito G.C. Inhibition of Pseudomonas aeruginosa
virulence factors by subinhibitory concentrations of azithromycin and other macrolide
antibiotics. J Antimicrob Chemother 1993; 31:681-688.
59. Kawamura-Sato K., Iinuma Y., Hasegawa T., Yamashino T., Ohta M. Postantibiotic
suppression effect of macrolides on the expression of flagellin in Pseudomonas aeruginosa
and Proteus mirabilis. J Infect Chemother 2001; 7:51-54.
60. Lagrou K., Peetermans W.E., Jorissen M., Verhaegen J., Van Damme J., Van Eldere J.
Subinhibitory concentrations of erythromycin reduce pneumococcal adherence to respiratory
epithelial cells in vitro. J Antimicrob Chemother 2000; 46:717-723.
61. D.J. Wozniak and R. Keyser. Effects of subinhibitory concentrations of macrolide antibiotics
on Pseudomonas aeruginosa. Chest 2004; 125: 62S-69S.
62. Jacobs M.R., Felmingham D., Appelbaum P.C., Gruneberg R.N.; The Alexander Project
Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from
community-acquired respiratory tract infections to commonly used antimicrobial agents J
Antimicrob Chemother 2003; 52:229-246.
63. Mera R.M., Miller L.A., Daniels J.J., Weil J.G., Whi-te A.R. Increasing prevalence of
multidrug-resistant Streptococcus pneumoniae in the United States over a 10-year period:
Alexander Project. Diagn Microbiol Infect Dis 2005; 51:195-200.
64. Heilmann S., Beekmann S., Richter S., Garcia-de Lovias J., Doern G.. Antimicrobial
resistance with Streptococcus pneumoniae in 2003 – results of the multinational GRASP
surveillance program. In: Abstracts of the 14th European Congress of Clinical Microbiology
and Infectious Diseases, Prague, Chech Respublic, 1-4 May 2004 [abstract P1130].
65. Hiramatsu K., Ohama M., Mijajima Y., Kishi K., Mizunoe S., Tokimatsu I., et al.
Antimicrobial susceptibilities and analysis of genes related to penicillin or macrolide
resistance in Streptococcus pneumoniae. Int J Antimicrob Agents. 2004; 24:125-129.
66. Kozlov R.S., Sivaja O.V., Stratchounski L.S. 7-years monitoring of resistance of clinical
S.pneumoniae in Russia: results of prospective multicenter study (PEHASus). Proceedings of
45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2005
Dec 16-19; Washington DC
67. Козлов Р.С. Пути оптимизации мониторинга, профилактики и фармакотерапии
пневмококковых инфекций: Автореф. дис. д-ра мед. наук. - Смоленск, 2004. - 46 с.
68. Farrell D.J., Morrissey I., Bakker S., Felmingham D. Molecular characterization of macrolide
resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes
isolated from the PROTEKT 1999-2000 study. J Antimicrob Chemother 2002; 50 (Suppl
S1):39-47.
69. Farrell D.J., Jenkins S.G. Distribution across the USA of macrolide resistance and macrolide
resistance mechanisms among Streptococcus pneumoniae isolates collected from patients with
respiratory tract infections: PROTEKT US 2001-2002. J Antimicrob Chemother 2004; 54
(Suppl 1):i17-22.
70. R.J. Davidson, C.C.K.Chan, G. Doern, G.G. Zhanel. Macrolide-resistant Streptococcus
pneumoniae in Canada: correlation with azithromycin use. In: Abstracts of the 13th European
Congress of Clinical Microbiology and Infectious Diseases, Glasgow, UK, 10-13 May 2003
[abstract P1031].
71. Aspa J., Rajas O., Rodriguez de Castro F., e. a. Drug-resistant pneumococcal pneumonia:
clinical relevance and related factors. Clin Infect Dis 2004; 38:787-798.
72. Lynch III J.P., Martinez F.J.. Clinical revalence of macrolide-resistant Streptococcus
pneumoniae for community-acquired pneumonia. Clin Infect Dis 2002; 34 (Suppl 1):S27-46.
73. Kays M.B., Denys G.A. In vitro activity and pharmacodynamics of azithromycin and
clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary
pharmacokinetics. Clin Ther 2001 Mar; 23:413-424.
74. Noreddin A.M., Roberts D., Nichol K., Wierzbowski A., Hoban D.J., Zhanel G.G.
Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive
mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and
epithelial lining fluid free-drug concentrations. Antimicrob Agents Chemother 2002; 46:40294034.
75. Horvat T., Warkentine F., Li Y.. Bactericidal activity and postantibiotic effects of
clarithromycin against Streptococcus pneumoniae with the efflux mechanism of macrolide
resistance. In: Abstracts of the 14th European Congress of Clinical Microbiology and
Infectious Diseases, Prague, Chech Respublic, 1-4 May 2004 [abstract P1820].
76. Stein G.E., Schooley S. Comparative serum bactericidal activity of clarithromyein and
azithromycin against macrolide-sensitive and resistant strains of Streptococcus pneumoniae.
Diagn Microbiol Infect Dis 2001; 39:181-185.
77. Kaplan E.L., Johnson D.R., Del Rosario M.C., Horn D.L. Susceptibility of group A betahemolytic streptococci to thirteen antibiotics: examination of 301 strains isolated in the
United States between 1994 and 1997. Pediatr Infect Dis J 1999; 18:1069-1072.
78. Canton R., Loza E., Morosini I., Baquero F. Antimicrobial resistance amongst isolates of
Streptococcus pyogenes and Slaphylococcus aureus in the PROTEKT antimicrobial
surveillance programme during 1999-2000. J Antimicrob Chemother 2002; 50(Suppl Sl):9-24.
79. Richter S.S., Heilmann K.P., Beekmann S.E., Miller N.J., Miller A.L., Rice C.L., et al.
Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003.
Clin Infect Dis 2005; 41:599-608.
80. Kataja J., Huovinen P., Skurnik M., Seppala H. Erythromycin resistance genes in group A
streptococci in Finland. The Finnish Study Group for Antimicrobial Resistance. Antimicrob
Agents Chemother 1999; 43:48-52.
81. Ho P.L., Johnson D.R., Yue A.W., Tsang D.N., Que T.L., Beall B., Kaplan E.L.
Epidemiologic analysis of invasive and noninvasive group a streptococcal isolates in Hong
Kong. J Clin Microbiol 2003; 41:937-942.
82. Sivaja O., Kozlov R.S., Stratchounski L.S., PEHASus project group. Current state of
antimicrobial resistance of S.pyogenes (GAS) in Russia: results of prospective multicentre
study (PEHASus-I, PHASE “B”). Proceedings of the 1st FEMS Congress of European
Microbiologists. Ljubljana, Slovenia; June 29-July 3, 2003. P. 235.
83. Sauermann R., Gattringer R., Graninger W., Bux-ba-umA., Ge-orgopoulos A. Phenotypes of
macrolide resistance of group A streptococci isolated from outpatients in Bavaria and
susceptibility to 16 antibiotics. J Antimicrob Chemother 2003; 51:53-57.
84. Gattringer R., Sauermann R., Lagler H., Stich K., Buxbaum A., Graninger W., Georgopoulos
A. Anti-microbial susceptibility and macrolide resistance genes in Streptococcus pyogenes
collected in Austria and Hungary. Int J Antimicrob Agents 2004; 24:290-293.
85. Страчунский Л.С., Богданович Т.М. Состояние резистентности к антиинфекционным
химиопрепаратам в России. Практическое руководство по антиинфекционной
химиотерапии. Под ред. Страчунского Л.С., Белоусова Ю.Б., Козлова С.Н. - М.: Боргес,
2002. - С. 32-39.
86. Varaldo P.E., Debbia E.A., Nicoletti G., Pavesio D., Ripa S., Schito G.C., Tempera G.
Nationwide survey in Italy of treatment of Streptococcus pyogenes pharyngitis in children:
influence of macrolide resistance on clinical and microbiological outcomes. Artemis-Italy
Study Group. CID 1999; 29:869-873.
87. Bassetti M., Manno G., Collida A., Ferrando A., Gatti G., Ugolotti E., et al. Erythromycin
resistance in Streptococcus pyogenes in Italy. Emerg Infect Dis 2000; 6: 180-183.
88. Bergeron M.G., Bemier M., L’Ecuyer J. In vitro activity of clar­ithromycin and its 14hydroxy-metabolite against 203 strains of Haemophilus influenzae. Infection 1992; 20: 164167.
89. Fass R.J. Erythromycin, clarithromycin, and azithromycin: use of frequency distribution
curves, scattergrams, and regression analyses to compare in vitro activities and describe crossresistance. Antimicrob Agents Chemother 1993, 37: 2080-2086.
90. Thomsberry C., Sahm D.F., Kelly L.J., et al. Regional trends in antimicrobial resistance
among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella
caiarrhalis in the United States: results from the TRUST surveillance program, 1999-2000.
Clin Infect Dis 2002; 34 (Suppl 1): S4-S16.
91. Critchley I.A, Jones M.E., Heinze P.D., Hubbard D., Engler H.D., Evangelista A.T, e.a.. In
vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumoniae from North America and
Europe. Clin Microbiol Infect 2002; 8:214-221.
92. Helicobacter pylori: Review and update. Hospital Physician. May 2002, p. 23-31.
93. Malfertheiner P., Megraud F., O’Morain C., Hungin A.P., e.a.; European Helicobacter Pylori
Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection
- The Maastricht 2-2000 Consensus Report. Aliment Fharmacol Ther 2002; 16:167-180.
94. Meurer L.N., Bower D.J. Management of Helicobacter pylori infection. Am Fam Physician
2002; 65:1327-1336.
95. Megraud F. Basis for the management of drug-resistant Helicobacter pylori infection.
Drugs 2004; 64:1893-1904.
96. Glupczynski Y., Megraud F., Lopez-Brea M., Andersen L.P. European multicenter survey of
in vitro antimicrobial resistance in Helicobacler pylori. Eur J Clin Microbiol Infecl Dis 2000;
11:820-823.
97. Crone J., Granditsch G., Huber W.D., Binder C., Innerhofer A., Amann G., Hirschl A.M.
Helicobacler pylori in children and adolescents: increase of primary clarithromycin
resistance, 1997-2000. J Pediatr Gaslroenterol Nutr 2003; 36:368 371.
98. Bontems P., Devaster J.M., Corvaglia L., Dezsofi A., Van Den Borre C., Goutier S., et al.
Twelve year observation of primary and secondary antibiotic resistant Helicobocter pylori
strains in children. Pediatr Infect Dis J 2001; 20:1033-1038.
99. Boyanova L., Koumanova R., Gergova G., Popova M., Mitov I., Kovacheva Y., et al.
Prevalence of resistant Helicobocter pylori isolates in Bulgarian children. J Med Microbiol
2002; 51:786-790.
100. Dzierzanowska-Fangrat K., Rozynek E., Jozwiak P., Celinska-Cedro D., Madalinski K.,
Dzierzanowska D. Primary resistance to clarilhromycin in clinical strains of Helicobacter
pylori isolated from children in Poland. Inf J Aniimicrob Agents 2001; 18:387 -390.
101. Boyanova L., Mentis A., Gubina M., Rozynek E., Gosciniak G., Kalenic S., et al. The
status of antimicrobial resistance of Helicobacter pylori in Eastern Europe. Clin Microbiol
Infect 2002; 8:388-396.
102. Л.В. Кудрявцева, П.Л. Щербаков, И.О. Иваников, В.М. Говорун. Helicobacter pyloriинфекция: современные аспекты диагностики и терапии. Пособие для врачей - М.;
2004.
103. Megraud F. H.pylori antibiotic resistance: prevalence, importance, and advances in testing.
Gut 2004; 53:1374-1384.
104. Houben M.H., van de Beek D., Hensen E.F., Cra-en A. J., Rauws E.A., Tytgat G.N. A
systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial
resistance on eradication rates. Aliment Pharmacol Ther 1999; 3:1047-1055.
105. McMahon B.J., Hennessy T.W., Bensler J.M., Bruden D.L., Parkinson A.J., Morris J.M., et
al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment
outcomes for Helicobacter pylori infections. Ann Intern Med 2003; 139:463-469.
106. Cuchi Burgos E., Forne Bardera M., Quintana Riera S., Lite Lite J., Garau Alemany J.
Evolution of the sensitivity of 235 strains of Helicobocler pylori from 1995 to 1998 and
impact of antibiotic treatment Enferm Infecc Microbiol Clin 2002; 20:157-160.
107. Duck W.M., Sobel J., Pruckler J.M., Song Q., Swerdlow D., Friedman C., et al.
Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected
persons, United States. Emerg Infect Dis 2004; 10:1088-1094.
108. Gilbert K., Gleason P.P., Singer D.E., Marrie T.J., Coley C.M., Obrosky D.S., et al.
Variations in antimicrobial use and cost in more than 2,000 patients with community-acquired
pneumonia. Am J Med 1998; 104:17-27.
109. Marrie T.J., Lau C.Y., Wheeler S.L., Wong C.J., Vandervoort M.K., Feagan B.G. A
controlled trial of a critical pathway for treatment of community-acquired pneumonia.
CAPITAL Study Investigators. Commu-nity-Acquired Pneumonia Intervention Trial
Assessing Levofloxacin. JAMA 2000; 283:749-755.
110. Ewig S., Ruiz M., Torres A., Marco F., Martinez J.A., Sanchez M., Mensa J. Pneumonia
acquired in the community through drug-resistant S. pneumoniae. Am J Respir Crit Care Med
1999; 159:1835-1842.
111. Kelley M., Weber D.J., Gilligan P., Cohen M.S. Breakthrough pneumococcal bacteremia in
patients being treated with azithromyein and clarithromycin. Clin Infect Dis 2000; 31:10081011.
112. Lonks J., Garau J., Gomez L., Xercavins M., Ochoa de Echaguen A., Gareen I.F., e. a.
Failure of macrolide antibiotic in patients with bacteremia due to erythromycin-resistant
Streptococcus pneumoniae. Clin Infect Dis 2002; 35:556-564.
113. Rzeszutek M., Wierzbowski A., Hoban D., Conly J., Bishai W., Zhanel G.G. A review of
clinical failures associated with macrolide-resistant Streptococcus pneumoniae. Internat J
Antimicrob Agents 2004; 24: 95-104.
114. Niederman M.S., Mandell L.A., Anzueto A., Bass J.B., Broughton W.A., Campbell G.D., et
al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis,
assessment of severity, antimicrobial therapy and prevention. Am J Respir Crit Care Med
2001; 163:1730-1754.
115. Mandell L.A., Marrie T.J., Grossman R.F., et al. Canadian guidelines for the initial
management of community-acquired pneumonia: an evidence-based update by the Canadian
Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000; 31:383421.
116. Mandell L.A., Bartlett J.G., Dowell S.F., File T.M., Jr., Musher D.M., Whitney C.. Update
of Practice Guidelines for the management of community-acquired pneumonia in
immunocompetent adults. Clin Infect Dis 2003; 37:1405-1433.
117. Чучалин А.Г., Синопальников А.И., Яковлев С.В., Страчунский Л.С., Козлов Р.С.,
Рачина С.А.. Внебольничная пневмония у взрослых: практические рекомендации по
диагностике, лечению и профилактике. Пособие для врачей. 2003.
118. File T., Garau J., Blasi F., Chidiac C., Klugman K., Lode H., e. a. Guidelines for empiric
antimicrobial prescribing in community-acquired pneumonia. Chest 2004; 125: 1888-1901.
119. Thibodeau K.P., Viera A.J.. Atypical pathogens and challenges in community-acquired
pneumonia. Am Fam Physician 2004; 69:1699-1706.
120. Roig J., Sabria M., Alegre J., Gurdui M., Checa J.C. Spanish Study Group for Legionella.
Comparative randomized open multicentre trial assessing the efficacy and safety of
intravenous/oral azithromycin compared with intravenous/oral clarithromycin for the
treatment of community-acquired pneumonia due to Legionella pneumophila. In: Abstracts of
the 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Chech
Respublic, 1-4 May 2004 [abstract P433].
121. Gleason P.P., Kapoor W.N., Stone R.A., Lave J.R., Obrosky D.S., Schulz R., et al. Medical
outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines
for outpatients with community-acquired pneumonia. JAMA 1997; 278:32-39.
122. Stahl J.E., Barza M., DesJaidin J., Martin R., Eckman M.H. Effect of macrolides as part of
initial empiric therapy on length of stay in patients hospitalized with community-acquired
pneumonia. Arch Intern Med 1999; 159:2576-2580.
123. Martinez J.A., Horcajada J.P., Almela M., Marco F., Soriano A., Garcia E., et al. Addition
of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-
hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis
2003; 36:389-395.
124. Garcia Vazquez E., Mensa J., Martinez J.A., Marcos M.A., Puig J., Ortega M., Torres A.
Lower mortality among patients with community-acquired pneumonia treated with a
macrolide plus a beta-lactam agent versus a beta-lactam agent alone. Eur J Clin Microbiol
Infect Dis 2005; 24:190-195.
125. Ostapchuk M., Roberts D.M., Haddy R.. Commu-nity-acquired pneumonia in infants and
children. Am Fam Physician 2004; 70:899-908.
126. Doll H., Grey-Amante P., Duprat-Lomon I., Sagnier P.P., Thate-Waschke I., Lorenz J., et
al. Quality of life in acute exacerbation of chronic bronchitis: results from a German
population study. Respir Med 2002; 96:39-51.
127. Miravitlles M., Ferrer M., Pont A., Zalacain R., Alvarez-Sala J.L., Masa F., e.a.; IMPAC
Study Group. Effect of exacerbations on quality of life in patients with chronic obstructive
pulmonary disease: a 2 year follow up study.Thorax 2004; 59:387-395.
128. Miravitlles M, Murio C, Guerrero T, Gisbert R. Costs of chronic bronchitis and COPD: a 1year follow-up study. Chest 2003; 123:784-791.
129. Sethi S. The role of antibiotics in acute exacerbations of chronic obstructive pulmonary
disease. Curr Infect Dis Rep 2003; 5:9-15.
130. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000;
117(Suppl):380-385.
131. Guthrie R. Community-acquired lower respiratory tract infections: etiology and treatment.
Chest 2001; 120:2021-2034.
132. Snow V., Lascher S., Mottur-Pilson C., Snow V., La-scher S., Mottur-Pilson C.; Joint
Expert Panel on COPD of the American College of Chest Physicians and the American
College of Physicians-Amercian Society of Internal Medicine. The evidence base for
management of acute exacerbations of COPD: clinical practice guideline, part 1. Chest 2001;
119:1185-1189.
133. Чучалин А.Г., Синопальников А.И., Страчунсккий Л.С. Инфекции нижних
дыхательных путей. Практическое руководство по антиинфекционной химиотерапии
Под ред. Страчунского Л.С., Белоусова Ю.Б., Козлова С.Н. - М.: Боргес, 2002. - С. 219225.
134. Balter M.S., La Forge J., Low D.E., Mandell L., Gros-sman R.F.; Canadian Thoracic
Society; Canadian Infectious Disease Society. Canadian guidelines for the management of
acute exacerbations of chronic bronchitis.Can Respir J 2003; 10 (Suppl B):3B-32B.
135. Adier J.L., Jannetti W., Schneider D., Zhang J., Palmer R., Notario G. Phase III,
randomized, double-blind study of clarithromycin extended-release and immediate-release
formulations in the treatment of patients with acute exacerbation of chronic bronchitis. Clin
Ther 2000; 22:1410-1420.
136. Adam D., Glaser-Caldow E., Wachter J., Brueckner O.J., Hein J., Kroemer B., Hirsch J.
Comparative efficacy of clarithromycin modified-release and clarithromycin immediaterelease formulations in the treatment of lower respiratory tract infections. Clin Ther 2001;
23:585-595.
137. Allin D., James I., Zachariah J., Carr W., Cullen S., Middleton A., et al. Comparison of
once- and twice-daily clarithromycin in the treatment of adults with severe acute lower
respiratory tract infections. Clin Ther 2001; 23:1958-1968.
138. Nalepa P. Dobryniewska M., Busman T., Notario G. Short-course therapy of acute bacterial
exacerbation of chronic bronchitis: a double blind, randomized, multicenter comparison of
extended release vs. immediate release clarithromycin. Curr Med Res Opin 2003; 19:411-420.
139. Белов Б.С., Насонова В.А., Гришаева Т.П. Ревматологические аспекты
стрептококкового тонзиллита и современные подходы к его антибактериальной
терапии. Клиническая антимикробная химиотерапия 2000; 2: 52-56.
140. Shulman S.T. Acute streptococcal pharyngitis in pediatric medicine: current issues in
diagnosis and management. Paediatr Drugs 2003; 5: (Suppl 1): 13-23.
141. Bisno A.L., Gerber M.A., Gwaltney J.M., Bisno A..L, Gerber M.A., Gwaltney J.M. Jr, e.a.;
Infectious Diseases Society of America. Practice guidelines for the diagnosis and
management of group A streptococcal pharyngitis. Clin Infect Dis 2002; 35:113-125.
142. Brink A.J., Cotton M.F., Feldman C., Geffen L., Hendson W., Hockman M.H., e.a.;
Working Group of the Infectious Diseases Society of South Africa Guideline for the
management of upper respiratory tract infections. S Afr Med J 2004; 94:475-483.
143. Kaplan E.L., Gooch III W.M., Notario G.F., Craft J.C. Macrolide therapy of group A
streptococcal pharyngitis: 10 days of macrolide therapy (clarithromycin) is more effective in
streptococcal eradication than 5 days (azithromycin). Clin Infect Dis 2001; 32:1798-1802.
144. McCarty J., Hedrick J.A. Gooch W.M. Clarithromycin suspension vs. penicillin V
suspension in children with streptococcal pharyngitis. Adv Ther 2000; 17:14-26.
145. Takker L.I., Dzyublyk O., Busman T., Notario G. Comparison of five days of extendedrelease clarithromycin versus ten days of penicillin v for the treatment ofstreptococcal
pharyngitis/tonsillitis: results of a multicenter, double-blind, randomized study. Curr Med Res
Opin 2003; 19:421-429.
146. Facinelli B., Spinaci C., Magi G., Giovanetti E., E Varal-do P. Association between
erythromycin resistance and ability to enter human respiratory cells in group A streptococci.
Lancet. 2001; 358:30-33.
147. Syrogiannopoulos G.A., Bozdogan B., Grivea I.N., Ednie L.M., Kritikou D.I., Katopodis
G.D., e.a.; Hellenic Antibiotic-Resistant Respiratory Pathogens Study Group. Two dosages of
clarithromycin for five days, amoxicillin/clavulanate for five days or penicillin V for ten days
in acute group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J 2004; 23:857-865.
148. Янов Ю.К., Рязанцев С.В., Страчунский Л.С. Стецюк. O. У., Каманин Е.И.,
ТарасовА.А., и др. Практические рекомендации по антибактериальной терапии
синусита. КМАХ 2003; 5:167-174.
149. Brook I., Gooch W.M., Jenkins S.G., et al. Medical management of acute bacterial sinusitis.
Ann. Otol. Rhinol. Laryngol. 2000; 109 (Suppl.):1-20.
150. Sinus and Allergy Health Partnership. Antimicrobial treatment guedelines for acute
bacterial rhinosinusitis. Otolaryngol. Head Neck Surg. 2004; 130 (1) (Suppl.):1-45.
151. Dubois J., Saint-Pierre C., Temblay С. Efficacy of clarithromycin vs. amoxicillin/
clavulanate in the treatment of acute maxillary sinusitis. Ear Nose Throat J 1993; 72:804-810.
152. Riffer E., Spiller J., Palmer R., Shortridge V., Busman T.A., Valdes J. Once daily
clarithromycin extended-release vs twice-daily amoxicillin/clavulanate in patients with acute
bacterial sinusitis: a randomized, investigator-blinded study. Curr Med Res Opin 2005; 21:6170.
153. Breuer T., Graham D.Y. Costs of diagnosis and treatment of Helicobacter pylori infection:
when does choosing the treatment regimen based on susceptibility testing become cost
effective? Am J Gastroenterol 1999; 94:3075-3076.
154. Giamarellos-Bourboulis E.J., Adamis T., Laouta-ris G., Sabracos L., Koussoulas V.,
Mouktaroudi M., et al. Immunomodulatory clarithromycin treatment of experimental sepsis
and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob
Agents Chemother 2004; 48:93-99.
155. Hirata T., Ogawa E., Takenaka K., Kawashita F. Suppression of postoperative systemic
inflammatory response syndrome with clarithromycin following lung cancer surgery. Eur
Surg Res 2004; 36: 13-19.
156. Poletti V., Chilosi M., Casoni G., Colby T.V. Diffuse panbronchiolitis. Sarcoidosis Vasc
Diffuse Lung Dis 2004; 21: 94-104.
157. Kudoh S., Uetake T., Hagiwara K., Hirayama M., Hus L.H., Kimura H., Sugiyama Y.
Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse
panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi. 1987; 25:632-642.
158. Kudoh S., Azuma A., Yamamoto M., Izumi T., Ando M. Improvement of survival in
patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit
Care Med 1998; 157: 829-1832.
159. Kadota J., Mukae H., Ishii H., Nagata T., Kaida H., Tomono K., Kohno S. Long-term
efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis.
Respir Med 2003; 97:844-850.
160. Rubin B.K., Henke M.O.. Immunomodulatory activity and effectiveness of macrolides in
chronic airway diseases. Chest 2004; 125:70S-78S.
161. Jaffe A, Francis J, Rosenthal M, Bush A. Long-term azithromycin may improve lung
function in children with cystic fibrosis [letter]. Lancet 1998; 351:420.
162. Equi A., Balfour-Lynn I.M., Bush A., Rosenthal M. Long term azithromycin in children
with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002; 360:978984.
163. Wolter J., Seeney S., Bell S., Bowler S., Masel P., McCormack J. Effect of long term
treatment with azithromycin on disease parameters in cystic fibrosis: a randomised
trial.Thorax 2002; 57:212-216.
164. 164. Ordonez C.L., Stulbarg M., Grundland H., Liu J.T., Boushey H.A. Effect of
clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic
fibrosis: a pilot study. Pediatr Pulmonol 2001; 32:29-37.
165. 165. Zeiger R.S., Schatz M,. Sperling W., Simon R.A., Stevenson D.D. Efficacy of
troleandomycin in outpatients with severe, corticosteroid-dependent asthma. J Allergy Clin
Immunol 1980; 66:438-446.
166. Ball B.D., Hill M.R., Brenner M., Sanks R., Szefler S.J. Effect of low-dose troleandomycin
on glucocorticoid pharmacokinetics and airway hyperresponsiveness in severely asthmatic
children. Ann Allergy. 1990; 65:37-45.
167. Kamada A.K., Hill M.R., Ikle D.N., Brenner A.M., Szefler S.J. Efficacy and safety of lowdose troleandomycin therapy in children with severe, steroid-requiring asthma. J Allergy Clin
Immunol 1993; 91:873-882.
168. Amayasu H., Yoshida S., Ebana S., Yamamoto Y., Nishikawa T., Shoji T., et al.
Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic
inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000; 84:594-598.
169. Gotfried M.H., Jung R., Messick C., Rubinstein I., Garey K.W., Rodvold K.A., Danziger
L.H. Placebo controlled trial evaluating the efficacy of clarithromycin in subjects with
cotricosteroid-dependent asthma. JAC 1999; 44 (Suppl):100.
170. Garey K.W., Rubinstein I., Gotfried M.H., Khan I.J., Varma S., Danziger L.H. Long-term
clarithromycin decreases prednisone requirements in elderly patients with prednisonedependent asthma. Chest 2000; 118:1826-1827.
171. Nishi K., Mizuguchi M., Tachibana H., Ooka T., Amemiya T., Myou S., et al. Effect of
clarithromycin on symptoms and mucociliary transport in patients with sino-bronchial
syndrome. Nippon Kyobu Shikkan Cakkai Zasshi 1995; 33:1392-1400.
172. Gotfried M.H.. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest
2004; 125:52S-61S.
173. Hashiba M., Baba S. Efficacy of long-term administration of clarithromycin in the treatment
of intractable chronic sinusitis. Acta Otolaryngol 1996; 525 (Suppl):73-78.
174. MacLeod C.M., Hamid Q.A., Cameron L., Tremblay C., Brisco W. Anti-inflammatory
activity of clarithromycin in adults with chronically inflamed sinus mucosa. Adv Ther 2001;
18:75-82.
175. Yamada T., Fujieda S., Mori S., Yamamoto H., Sai-to H. Macrolide treatment decreased the
size of nasal polyps and IL-8 levels in nasal lavage. Am J Rhinol 2000; 14:143-148.
176. Nixon L.S., Boorman J., Papagiannis A.J., et al. Circulation and airways antibiotic
inflammatory markers in chronic obstructive pulmonary disease (COPD) during an
exacerbation [absrtact]. Available from www.abstracts-on-line.com/abstracts/ATSALL.
177. MacLeod C.M. Mucolytic effect of clarithromycin modified-release in chronic bronchitis
[absrtact]. Spanish J Chemother 2000; 13: (Suppl 2): 94.
178. Benerjee D., Honeybourne D., Khair O.A. The effect of oral clarithromycin on bronchial
airway inflammation in moderate-to severe stable COPD: a randomized controlled trial. Treat
Respir Med 2004; 3:59-65.
179. Benerjee D., Honeybourne D., Khair O.A. The effect of oral clarithromycin on health status
and sputum bacteriology in stable COPD. Respir Med 2005; 99:208-215.
180. Gooderham M.J., Bolli P., Fernandez P.G. Concomitant digoxin toxicity and warfarin
interaction in a patient receiving clarithromycin. Ann Pharmacother 1999; 33:796-799.
181. Recker M.W., Kier K.L. Potential interaction between clarithromycin and warfarin. Ann
Pharmacother 1997; 31:996-998.
182. S. Trivedi, J.Hyman, E.Lichstein. Clarithromycin and digoxin toxicity. Ann Intern Med
1998; 128:604.
183. Nawarskas J.J., McCarthy D.M., Spinler S.A. Digoxin toxicity secondary to clarithromycin
therapy. Ann Pharmacother 1997; 31:864-866.
184. Hirata S., Izumi S., Furukubo T., Ota M., Fujita M., Yamakawa T., et al. Interactions
between clarithromycin and digoxin in patients with end-stage renal disease. Int J Clin
Pharmacol Ther 2005; 43:30-36.
185. Paar D., Terjung B., Sauerbruch T. Life-threatening interaction between clarithromycin and
disopyramide. Lancet 1997; 249:326-327.
186. Amsden G.W. Macrolides versus azalides: a drug interaction update. Ann Pharmacother
1995; 29:906-917.
187. Yasui N., Otani K., Kaneko S., Shimoyama R., Ohkubo T., Sugavara K. Carbamazepine
toxicity induced by clarithromycin coadministration in psychiatric patients. Int Clin
Psychopharmacol 1997; 12:225-229.
188. Grunden J.W., Fisher K.A. Lovastatin-induced rhabdomyolysis possibly associated with
clarithromycin and azithromycin. Ann Pharmacother 1997; 31:859-863.
189. Gorski J.C., Jones D.R., Haehner­Daniels B.D., Hamman M.A., O’Mara E.M. Jr, Hall S.D.
The contribution of intestinal and hepatic CYP 3A to the interaction between midazolam and
clarithromycin. Clin Pharmacol Ther 1998; 64:133-143.
190. Yeates R.A., Lauten H., Zimmerman T. Interaction between midazolam and clarithromycin:
comparison with azithromycin. Int J Clin Pharmacol Ther 1996; 34:400-405.
191. Flockhart D.A., Richard E., Woosley R.L., Pearle P.L., Drici M.D.A. Metabolic interaction
between clarithromycin and pimozide may result in cardiac toxicity. Clin Pharmacol Ther
1996; 59:189.
192. Greenblatt D.J., von Moltke L.L., Harmatz J.S., Counihan M., Graf J.A., Durol A.L., et al.
Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and
dynamic consequences. Clin Pharmacol Ther 1998; 64:278-285.
193. Piquette R.K. Torsade de pointes induced by cisapride/clarithromycin interaction. Ann
Pharmacother 1999; 33:22-26.
194. van Haarst A.D., van ‘t Klooster G.A., van Gerven J.M., Schoemaker R.C., van Oene J.C.,
Burggraaf J., et al. The influence of cisapride and clarithromycin on QT intervals in healthy
volunteers. Clin Pharmacol Ther 1998; 64:542-546.
195. Spicer S.T., Liddle C., Chapman J.R., Barclay P., Nanki­vell B.J., Thomas P., O’Connell
P.J. The mechanism of cyclosporine toxicity induced by clarithromycin. Br J Clin Pharmacol
1997; 43:194-196.
196. Horowitz R.S., Dart R.C., Gomez H.F. Clinical ergotism with lingual ischemia induced by
clarithromycin-ergotamine interaction. Arch Intern Med 1996; 156:456-458.
197. Byanova L., Spassova Z., Kroslev Z., Petrov S., Stancheva I., Docheva J., et al.
Characteristics and trends in macrolide resistance among Helicobacter pylori strains isolated
in Bulgaria over four years. Diagn Microbiol Infect Dis 1999; 34:309-313.
198. Bago J., Halle Z.B., Strinic D., Kucisec N., Jandric D., Bevanda M., et al. The impact of
primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs omeprazole
based one-week triple therapies in H. pylori eradication a randomised controlled trial. Wen
Klin Wochenschr 2002; 114:448-453.
199. Megraud F. Surveillance de la resistance de Helicobacter pylori aux antibiotiques. In:
Surveillance nalionale des maladies infectieuses 1998-2000, St Maurice, France: Inslilul de
Veille Sanilaire, 2003:327-329.
200. Wolle K., Leodolter A., Malfertheiner P, Konig W. Antibiotic susceptibility of Helicobacter
pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 2002;
51:705-709.
201. Toracchio S., Marzio L. Primary and secondary antibiotic resistance of Helicobacter pylori
strains isolated in central Italy during the years 1998-2002. Dig Liver Dis 2003; 35:541-545.
202. Pilotto A., Rassu M., Leandro G., Franceschi M., Di Mario F.; Interdisciplinary Group for
the Study of Ulcer Prevalence or Helicobocter pylori resistance to antibiotics in Northeast
Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer. Dig Liver
Dis 2000; 32:763-768.
203. Debets-Ossenkopp Y.J., Herscheid A.J., Pot R.G., Kuipers E.J., Kusters J.G.,
Vandenbroucke-Grauls C.M. Prevalence of Helicobacler pylori resistance to metronidazole,
clarithromycin, amoxicillin, lelracycllne and trovafloxacm in The Netherlands. J Antimicrob
Chemother 1999; 43:511-515.
204. Cabrita J., Oleastro M., Matos R., Manhente A., Cabral J., Barros R., et al. Features and
trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J
Antimicrob Chemother 2000; 46:1029-1031.
205. Megraud F., Lehn N., Lind T., Bayerdorffer E., O’Morain C., Spiller R., et al.
Antimicrobial susceptibility testing of Helicobacler pylori in a large multilcentre trial: the
MACH 2 study. Anilmicrob Agents Chemother 1999; 43:2747-2752.
206. Parsons H.K., Carter M.J., Sanders D.S., Winstanley T., Lobo A.J. Helicobacter pylori
antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic
status. Aliment Pharmacol Ther 2001; 15:1473-1478.
207. Torres J., Camorlinga-Ponce M., Perez-Perez G., Madrazo-De la Garza A., Dehesa M.,
Gonzalez-Valencia G., Munoz O. Increasing multidrug resistance in Helicobacter pylori
strains isolated from children and adults in Mexico. J Clin Microbiol 2001; 39:2677-2680.
208. Osato M.S., Reddy R., Reddy S.G., Penland R.L., Malaty H.M., Graham D.Y. Pattern of
primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United
States. Arch Intern Med 2001; 161:1217-1220.
209. Prazeres Magalhaes P., De Magalhaes Queiroz D.M., Campos Barbosa D.V., Aguiar Rocha
G., Nogueira Mendes E., Santos A. Helicobacler pylori primary resistance to metronidazole
and clarithromycin in Brazil. Antimicrob Agents Chemother 2002; 46:2021-2023.
210. Mohammadi M., Doroud D., Massarrat S., Farahvash M J. Clarithromycin resistance in
Iranian H. pylori strains before introduction of clarithromycin. Helicobocter 2003; 8:79-80.
211. Samra Z., Shmuely H., Niv Y., Dinari G., Passaro D.J., Geler A., et al. Resistance of
Helicobacter pylori isolated in Israel to metronidazole, clarithromycin, tetracycline,
amoxicillin and cefixime. J Antimicrob Chemother 2002; 49:1023-1026.
212. Ling T.K., Leung W.K., Lee C.C., Ng E.K., Yung M.Y., Chung S.S., et al. The
antimicrobial susceptibility of Helicobacter pylori in Hong Kong (1997-2001). Helicobacter
2002; 7:327-329.
213. Perez Aldana L., Kato M., Nakagawa S., Kawarasaki M., Nagasako T., Mizushima T., et al.
The relationship between consumption of antimicrobial agents and the prevalence of primary
Helicobacter pylori resistance Helicobacter 2002; 7:306-309.
214. Kim J.J., Reddy R., Lee M., Kim J.G., El-Zaatari F.A., Osato M.S., et al. Analysis of
metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from
Korea. JAC 2001; 47:459-461.
215. Teo E.K., Fock K.M., Ng T.M., Khor C.J., Tan A.L. Metronidazole-resislant Helicobocter
pylori in an urban Asian population. J Gastroenterol Hepatol 2000; 15:494-497.
216. Genne D., Siegrist H.H., Humair L., Janin-Jaquat B., de Torrente A. Clarithromycin versus
amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. Eur J Clin
Microbiol Infect Dis 1997; 16: 783-788.
217. Ramirez J., Nguyen T.H., Tellier G., Coppola G., Bettis R.,Dolmann A., et al. Once daily
400 mg oral gatifloxacin (GAT) vs. twice daily 500 mg oral clarithromycin (CLA) in the
treatment of community-acquired pneumonia (CAP). In: Proceedings of the Program and
Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy,
San Francisco, CA, 26-29 September 1999 [abstract 2242].
218. Moola S., Hagverg L., Churchyard G.A., Dylewski J.S., Sedani S., Staley H. A multicenter
study of grepafloxacin and clarithromycin in the treatment of patients with communityacquired pneumonia. Chest 1999; 116:974-983.
219. Drnec J., Vance A., Avila M., Morris D., Busman T., Notario G. Safety and efficacy
comparison of clarithromycin immediate release with trovafloxacin in community-acquired
pneumonia. In: Proceedings of the Program and Abstracts of the International Conference on
Macrolides, Azalides, Streptogramins, Ketolides, and Oxazolidinones, Seville, Spain, 26-28
January 2000 [abstract 04.25].
220. Hatipoglu O.N., Tasan Y. A comparative efficacy and safety study of clarithromycin,
roxithromycin and erythromycin stearate in mild pneumonia. Yonsei Med J 2000; 41:340344.
221. Hoeffken G., Meyer H.P., Winter J., Verhoef L., for the CAP1 Study Group. The efficacy
and safety of two oral moxifloxacin regimens (200 mg or 400 mg once-daily x 10 days)
compared to oral clarithromycin (500 mg twice-daily x 10 days) in the treatment of
community-acquired pneumonia. Respir Med 2001; 95:553-564.
222. Gotfried M.H., Dattani D., Riffer E., Devcich K.J., Busman T.A., Notario G.F., Palmer
R.N. A controlled, double-blind, multi-center study comparing clarithromycin extendedrelease tablets and levofloxacin tablets in the treatment of community-acquired pneumonia.
Clin Ther 2002: 24;736-751.
223. Sokol W.N., Sullivan J.G., Acampora M.D., Busman T.A., Notario G.F. A prospective,
double-blind, multi-center study comparing clarithromycin extended-release with
trovafloxacin in patients with community-acquired pneumonia. Clin Ther 2002; 24:605-615.
224. Bonvehi P., Weber K., Busman T., Shortridge D., Notario G. Comparison of clarithromycin
and amoxicillin/clavulanic acid for community-acquired pneumonia in a era of drug-resistant
Streptococcus pneumoniae. Clin Drug Invest 2003; 23:491-501.
225. Lode H., Aronkyto T., Chuchalin A.G., Jaaskevi M., Kahnovskii I., Kleutgens K.;
International Gatifloxacin Study Group. A randomised, double-blind, double-dummy
comparative study of gatifloxacin with clarithromycin in the treatment of communityacquired pneumonia. Clin Microbiol Infect 2004; 10:403-408.
226. Chodosh S., Schreurs A., Siami G., Barkman H.W. Jr, Anzueto A., Shan M., e. a. Efficacy
of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of
chronic bronchitis. Clin Infect Dis 1998; 27:730-738.
227. Zienng W., McElvaine P. Randomized comparison of once-daily ceftibuten and twice-daily
clarithromycin in the treatment of acute exacerbation of chronic bronchitis. Infection 1998;
26:68-75.
228. DeAbate C.A., Myers D., Henry D., e. a. Efficacy and tolerability of once-daily
grepafloxacin compared with clarithromycin in the treatment of acute bacterial exacerbations
of chronic bronchitis. Clin Drug Invest 1999; 17:21-31.
229. Langan С.Е., Zuck P., Vogel F., McIvor A, Peirzchala W, Smakal M, et al. Randomized,
double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in
patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother
1999; 44:515-523.
230. Wilson R., Kubin R., Ballin I., Deppermann K.M., Bassaris H.P., Leophonte P., et al. Five
day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of
acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 44:501-513.
231. Lipsky BA, Unowsky J, Zhang H. Townsend L, Talbot GH. Treating acute bacterial
exacerbations of chronic bronchitis in patients unresponsive to previous therapy: sparfloxacin
versus clarithromycin. Clin Ther 1999; 21:954-965.
232. Chodosh S., DeAbate C.A., Haverstock D., Aneiro L., Church D. and the Bronchitis Study
Group. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of
chronic bronchitis. Resp Med 2000; 94:18-27.
233. Anzueto A., Fisher C.L., Busman T., Olson C.A. Comparison of the efficacy of extendedrelease clarithromycin tablets and amoxicillin/clavulanale tablets in the treatment of acute
exacerbation of chronic bronchitis. Clin Ther 2001; 23:72-86.
234. Gotfried М.H., DeAbate C.A., Fogarty C., Mathew C.P., Sokol W.N. Comparison of 5-day,
short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin
therapy for acute exacerbation of chronic bronchitis. Clin Ther 2001; 23:97-107.
235. Martinot J.B., Carr W.D., Cullen S., Heredia Budo J.L., Bauer K., MacLeod C., e. a.;
Clarithromycin Once-a-Day Study Group. A comparative study of clarithromycin modified
release and amoxicillin/clavulanic acid in the treatment of acute exacerbation of chronic
bronchitis. Adv Ther 2001; 18:1-11.
236. Wilson R., Schentag J.J., Ball P., Mandell L., for the 068 Study Group. A comparison of
gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term
clinical outcomes. Clin Ther 2002; 24:639-652.
237. Lode H., Mauch H., Schafer V., Eller J., Linnhoff A., and the ETIC study group. Influence
of levofloxacin (LFX) compared with Clarithromycin (CLA) on the infection-free interval in
patients with chronic bronchitis. International congress of chemotherapy, Durban, South
Africa, 7-10 June 2003 [Poster P1122].
238. Swanson R.N., Lainez-Ventosilla A., De Salvo M.C., Dunne M.W., Amsden G.W. Oncedaily azithromycin for 3 days compared with clarithromycin for 10 days for acute
exacerbation of chronic bronchitis: a multicenter, double-blind, randomized study. Treat
Respir Med 2005; 4:31-9.
239. Levenstein J.H. Clarithromycin versus penicillin in the treatment of streptococcal
pharyngitis. J Antimicrob Chemother 1991; 27(Suppl A):67-74.
240. Bachand RT. A comparative study of clarithromycin and penicillin VK in the treatment of
outpatients with streptococcal pharyngitis. J Antimicrob Chemother 1991; 27(Suppl A):75-82.
241. Stein G.E., Christensen S., Mummaw N. Comparative study of clarithromycin and
penicillin V in the treatment ofstreptococcal pharyngitis. Eur J Clin Microbiol Infect Dis
1991; 10:949-953.
242. Schrock C.G. Clarithromycin vs. penicillin in the treatment ofstreptococcal pharyngitis. J
Fam Pract 1992; 35:622-626.
243. Still J.G., Hubbard W.C., Poole J.M., Sheaffer C.I., Chartrand S., Jacobs R. Comparison of
clarithromycin and penicillin VK suspensions in the treatment of children with streptococcal
pharyngitis and review of currently available alternative antibiotic therapies. Pediatr Infect
Dis J 1993; 12 (Suppl 3):S134-141.
244. Kearsley N.L., Campbell A., Sanderson A.A, Weir R.D, Kamdar M.K., Coles SJ.
Comparison of clarithromycin suspension and amoxycillin syrup for the treatment of children
pharyngitis and/or tonsillitis. Br J Clin Pract 1997; 51:133-137.
245. Venuta A., Laudizi L., Beverelli A., Bettelli F., Milioli S., Garetti E. Azithromycin
compared with clarithromycin for the treatment of streptococcal pharyngitis in children. J Int
Med Res 1998; 26:152-158.
246. Quinn J., Ruoff G.E., Ziter P.S. Efficacy and tolerability of 5-day, once-daily telithromycin
compared with 10-day, twice-daily clarithromycin for the treatment of group A beta-
hemolytic streptococcal tonsillitis/pharyngitis: a multicenter, randomized, double-blind,
parallel-group study. Clin Ther 2003; 25:422-433.
247. Stefansson P., Jacovides A., Jablonicky P., Sedani S., Staley H. Cefuroxime axetil versus
clarithromycin in the treatment of acute maxillary sinusitis. Rhinology 1998; 36:173-178.
248. Adelglass J., Jones T.M., Ruoff G., Kahn J.B., Wiesinger B.A., Rielly-Gauvin K., Siu C.O.
A multicenter, investigator-blinded. randomized comparison of oral levofloxacin and oral
clar-ithromycin in the treatment of acute bacterial sinusitis. Phamacotherapy 1998; 18:12551263.
249. Lasko В., Lau C.Y., Saint-Pierre C., Reddington J.L., Martel A., Anstey R.J. Efficacy and
safety of oral levofloxacin compared with clarithromycin in the treatment of acute sinusitis in
adults: a multicentre. double-blind, randomized study. J Int Med Res 1998; 26:281-291.
250. Fogarty C. Gatifloxacin vs. clarithromycin in the management of acute sinusitis. J Resp Dis
1999; 20:817-822.
251. Henry D.C., Moller D.J. Jr, Adelglass J., Scheld W.M., Jablonski C.K., Zhang H., et al.
Comparison of sparfloxacin and clarithromycin in the treatment of acute bacterial maxillary
sinusitis. Clin Ther 1999; 21:340-352.
252. Clifford .К, Huck W., Shan M., Tosiello R., Echols R.M. Heyd A. Double-blind
comparative trial of ciprofloxacin versus clar-ithromycin in the treatment of acute bacterial
sinusitis. Ann Otol Rhinol 1999; 108:360-367.
253. Murray J.J., Solomon E., McCluskey D., Zhang J., Palmer R., Notario G. Phase III,
randomized, double-blind study of clarithromycin extended-release and immediate-release
formulations in the treatment of adult patients with acute maxillary sinusitis. Clin Ther 2000;
22:1421-1432.
254. Bochenek W.J., Peters S., Fraga P.D., Wang W., Mack M.E., Osato M.S., e.a.; Helicobacter
pylori Pantoprazole Eradication (HELPPE) Study Group.Bochenek WJ, Peters S, Froga PD,
el cil. Helicobacter pylori Pantoprazole Eradication (HELPPE) Study Group. Eradication of
Helicobacler pylori by 7-day triple therapy regimens combining pantoprazole with
clorilhromycin, metronidazole or amoxicillin in patients with peptic ulcer disease; results of
two double blind, randomized studies. Helicobacter 2003; 8:626 642.
255. Hoshiya S., Watanabe K., Tokunaga K., Tanaka A., Ninomiya H., Shingaki M., et al.
Relationship between eradication therapy and clarithromycin-resistant Helicobacler pylori in
Japan. J Gastroenterol 2000; 35:10-14.
256. Katelaris P.H., Forbes G.M., Talley N.J., Crotty B. A randomized comparison of quadruple
and triple therapies for Helicobacter pylori eradication: the QUADRATE study.
Gastroenterology 2002; 123:1763-1769.
257. Kawabata H., Habu Y., Tomioka H., Kutsumi H., Kobayashi M., Oyasu K., et al. Effect of
different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance
on the eradication rate of Helicobacter pylori infection by a 1 week regimen of proton pump
inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther 2003; 17:259-264.
258. Kihira K., Satoh K., Saifuku K., Kawakami S., Fukazawa K., Ishino Y., et al. Rabeprazole,
amoxycillin and low-or high dose clarithromycin for cure of Helicobacter pylori infection.
Aliment Pharmacol Ther 2000; 14:1083-1087.
259. Lamouliatte H., Samoyeau R., De Mascarel A., Megra-ud F. Double vs. single dose of
pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of
Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 1999;
13:1523-1530.
260. Lamouliatte H., Megraud F., Delchier J.C., Bretagne J.F., Courillon-Mallet A., De Korwin
J.D., et al.; Multicentre Study Group. Second-line treatment for failure to eradicate
Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment
Pharmacol Ther 2003; 18:791-797.
261. Lehmann F.S., Drewe J., Terracciano L., Beglinger C. Effect of ornidazole and
clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease.
Aliment Pharmacol Ther 2000; 14:305-309.
262. Lind T., Megraud F., Unge P., Bayerdorffer E., O’morain C., Spiller R., et al. The MACH2
study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies.
Gastroenterology 1999; 116:248-253.
263. McMahon B.J., Hennessy T.W., Bensler J.M., Bruden D.L., Parkinson A.J., Morris J.M., et
al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment
outcomes for Helicobacter pylori infections. Ann Intern Med 2003; 139:463-469.
264. Miki I., Aoyama N., Sakai T., Shirasaka D., Wambura C.M., Maekawa S., e.a.. Impact of
clarithromycin resistance and CYP2C 19 genetic polymorphism on treatment efficacy of
Helicobacter pylori infection with lansoprazole-or rabeprazole-based triple therapy in Japan.
Eur J Gastroenterol Hepatol 2003; 15:27-33.
265. Murakami K., Sato R., Okimoto T., Nasu M., Fujioka T., Kodama M., et al. Eradication
rates of clarithromycin resistant Helicobacler pylori using either rabeprazole or lansoprazole
plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 2002; 16:1933-1938.
266. Peitz U., Sulliga M., Wolle K., Leodolter A., Von Arnim U., Kahl S., et al. High rate of
post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure
Helicobacter pylori infection: impact of two second line therapies in a randomized study.
Aliment Pharmacol Ther 2002; 16:315-324.
267. Poon S.K., Chang C.S., Su J., Lai C.H., Yang C.C., Chen G.H., Wang W.C. Primary
resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori
lansoprazole-based triple therapies. Aliment Pharmacol Ther 2002; 16:291-296.
268. Horstkotte D., Follath F., Gutschik E., Lengyel M., Oto A., Pavie A., et al.; Task Force
Members on Infective Endocarditis of the European Society of Cardiology; ESC Committee for
Practice Guidelines (CPG); Document Reviewers. Guidelines on prevention, diagnosis and
treatment of infective endocarditis executive summary; the task force on infective endocarditis of
the European society of cardiology. Eur Heart J 2004; 25:267-276.